

COVID-19 Vaccine Safety Technical (VaST) Work Group


Assessment

Grace M. Lee, MD MPH

Advisory Committee on Immunization Practices

April 23, 2021

Dynamic decision-making process



COVID-19 Vaccine Safety Technical (VaST) Work Group

Objectives

- Review, evaluate, and interpret post-authorization/approval COVID-19 vaccine safety data
- Serve as the central hub for technical subject matter expertise from federal agencies conducting post-authorization/approval safety monitoring
- Advise on analyses, interpretation, and data presentation
- Provide updates to the ACIP COVID-19 Vaccines Work Group and the ACIP on COVID-19 vaccine safety

VaST Activities

Pre-authorization

Jun-Dec 2020

- 14 meetings to prepare for vaccine safety surveillance in the U.S.

ACIP Recommendations

- Dec 12 – Pfizer/BioNTech
- Dec 14 – 1st dose administered in U.S.
- Dec 19 – Moderna
- Feb 28 – Janssen

Post-authorization

Dec 21-present

- 17 independent meetings to review vaccine safety data across multiple surveillance systems

VaST Meeting - April 12

CVST with thrombocytopenia

- 6 cases of CVST with thrombocytopenia identified as a rare, but serious adverse event following Janssen vaccine
- Risk factors for CVST with thrombocytopenia not well understood
- Timely and transparent communication with healthcare providers and the public is crucial to maintain confidence in the vaccination program

HAN Communication – April 13

Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine



- Recommendations for Clinicians: diagnosis and treatment
 - Evaluate patients with a screening PF4 enzyme-linked immunosorbent (ELISA) assay as would be performed for autoimmune HIT. Consultation with a hematologist is strongly recommended.
 - Do not treat with heparin, unless HIT testing is negative
- Recommendations for Public Health: case reporting through VAERS
 - Encourage healthcare providers and the public to report all serious and life-threatening adverse events and deaths following receipt of COVID-19 vaccines to VAERS
- Recommendations for the Public: clinical signs and symptoms to monitor
 - Contact healthcare provider, or seek medical care if you develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination with the J&J COVID-19 vaccine

ACIP Meeting – April 14

CVST with thrombocytopenia

- Review of reported cases of CVST with thrombocytopenia after COVID-19 vaccines
- Discussion about the need for additional information to support evidence-based decision making, including
 - Age and gender-specific risk estimates
 - Evaluation of the benefit-risk balance of using Janssen vaccine in specific subgroups

VaST Meeting - April 19

Thrombosis with Thrombocytopenia Syndrome

- Review of new Brighton Collaboration definition of Thrombosis with Thrombocytopenia Syndrome (TTS)
 - Will facilitate investigation across surveillance systems
- Health Network Alert (HAN) supported enhanced case finding
 - Age and gender-specific rates of TTS following Janssen vaccine requested for risk assessment
- Review of data from VSD RCA and VA RCA
 - No safety signal identified for CVST, other thromboembolic disease, or thrombocytopenia identified following Janssen vaccine (>200,000 doses)
- Update from Global Advisory Committee on Vaccine Safety (GACVS) on TTS cases following AstraZeneca vaccine

VaST and CVWG Meeting - April 22

- Risk for TTS following Janssen vaccine
 - 7 per million doses in females <50 years* (highest in 30-39 years)
 - <1 per million doses in female 50+ and males*
- Other potential risk factors
 - Obesity (BMI>30), OCP use, hypothyroidism, hypertension
- Outcomes
 - 3 deaths, 7 remain hospitalized (4 in ICU), 5 discharged home
- Benefit-risk assessment and Evidence-to-Recommendation framework discussed

**Includes all doses (not adjusted for follow-up time)*

VaST Summary

- Risk of TTS appears to be highest in female <50 years
 - Other risk factors for TTS not well established yet
- Risk mitigation strategies
 - Minimize exposure in high-risk populations
 - Increase awareness & ensure timely diagnosis and management of TTS
 - Educate patients about benefits and risks of available vaccines
- VaST will continue to monitor TTS, thromboembolic disease, and thrombocytopenia in all available vaccine safety surveillance systems
- VaST will update the ACIP COVID-19 vaccines workgroup, ACIP secretariat and ACIP on a regular basis

VaST Members

VaST Members

Grace Lee (ACIP)
Robert Hopkins (NVAC)
Matt Daley
Veronica McNally
Keipp Talbot
Kathy Edwards
Lisa Jackson
Laura Riley
Robert Schechter
Patricia Whitley-Williams

CDC Co-Leads

Lauri Markowitz
Melinda Wharton

Ex Officio and Liaison Representatives

Tatiana Beresnev (NIH)
Karen Farizo; Hui Lee Wong (FDA)
Judith Steinberg (OIDP)
Jeffrey Kelman (CMS)
Matthew Clark (IHS)
Mary Rubin (HRSA)
Fran Cunningham (VA)
Limone Collins (DoD)

Administrative Support

Susan Hiers
Jared Woo